Dietary supplementation with n-3-fatty acids in patients with pancreatic cancer and cachexia: marine phospholipids versus fish oil - a randomized controlled double-blind trial
Werner K, Küllenberg de Gaudry D, Taylor LA, Keck T, Unger C, Hopt UT, Massing U
Lipids in health and disease · 63 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Bundesministerium für Bildung und Forschung
- Organización sin fines de lucro
- Verein zur Förderung der Krebsmedizin - Kirstins Weg e.V.
- Subvenciones
- Bundesministerium für Bildung und Forschung (0315477B)
Según 2 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2017-06-02 · Lipids Health Dis · vol. 16 · número 1 · pág. 104
- Editorial
- BioMed Central
- Citado
- 85 citas · más que el 96% de estudios similares · 4.5× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 46 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Fatty Acid Research and Health · Nutrition and Health in Aging · Clinical Nutrition and Gastroenterology
- Palabras clave
- Fish oil, Pancreatic cancer, Medicine, Randomized controlled trial, Weight loss, Internal medicine, Gastroenterology, Clinical nutrition, Cancer, Quality of life (healthcare), Cachexia, Appetite, Obesity, Biology
- MeSH
- humans, pancreatic neoplasms, body weight, cachexia, dietary fats, unsaturated, fatty acids, omega-3, phospholipids, fish oils, double-blind method, quality of life, dietary supplements, adult, middle aged, female, male
7 autores
- Kristin Werner🇩🇪 · autor de correspondenciaUniversity of Freiburg; University Medical Center Freiburg
- Daniela Kuellenberg de Gaudry🇩🇪University of Freiburg; University Medical Center Freiburg
- Lenka A. Taylor🇩🇪Heidelberg University; University Medical Center Freiburg
- Tobias Keck🇩🇪University of Lübeck
- Clemens Unger🇩🇪University Medical Center Freiburg
- Ulrich Theodor Hopt🇩🇪University of Freiburg; University Medical Center Freiburg
- Ulrich Massing🇩🇪University of Freiburg; University Medical Center Freiburg
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Like many other cancer patients, most pancreatic carcinoma patients suffer from severe weight loss. As shown in numerous studies with fish oil (FO) supplementation, a minimum daily intake of 1.5 g n-3-fatty acids (n-3-FA) contributes to weight stabilization and improvement of quality of life (QoL) of cancer patients. Given n-3-FA not as triglycerides (FO), but mainly bound to marine phospholipids (MPL), weight stabilization and improvement of QoL has already been seen at much lower doses of n-3-FA (0,3 g), and MPL were much better tolerated. The objective of this double-blind randomized controlled trial was to compare low dose MPL and FO formulations, which had the same n-3-FA amount and composition, on weight and appetite stabilization, global health enhancement (QoL), and plasma FA-profiles in patients suffering from pancreatic cancer.
Methods
Sixty pancreatic cancer patients were included into the study and randomized to take either FO- or MPL supplementation. Patients were treated with 0.3 g of n-3-fatty acids per day over six weeks. Since the n-3-FA content of FO is usually higher than that of MPL, FO was diluted with 40% of medium chain triglycerides (MCT) to achieve the same capsule size in both intervention groups and therefore assure blinding. Routine blood parameters, lipid profiles, body weight, and appetite were measured before and after intervention. Patient compliance was assessed through a patient diary. Quality of life and nutritional habits were assessed with validated questionnaires (EORTC-QLQ-C30, PAN26). Thirty one patients finalized the study protocol and were analyzed (per-protocol-analysis).
Results
Intervention with low dose n-3-FAs, either as FO or MPL supplementation, resulted in similar and promising weight and appetite stabilization in pancreatic cancer patients. MPL capsules were slightly better tolerated and showed fewer side effects, when compared to FO supplementation.
Conclusion
The similar effects between both interventions were unexpected but reliable, since the MPL and FO formulations caused identical increases of n-3-FAs in plasma lipids of included patients after supplementation. The effects of FO with very low n-3-FA content might be explained by the addition of MCT. The results of this study suggest the need for further investigations of marine phospholipids for the improvement of QoL of cancer patients, optionally in combination with MCT.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.